[{"address1": "3020 Carrington Mill Blvd.", "address2": "Suite 475", "city": "Morrisville", "state": "NC", "zip": "27560", "country": "United States", "phone": "212 554 4484", "fax": "212 554 4531", "website": "https://www.tgtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.", "fullTimeEmployees": 374, "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Weiss Esq., J.D.", "age": 58, "title": "Chairman, CEO & President", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1970938, "exercisedValue": 0, "unexercisedValue": 26229992}, {"maxAge": 1, "name": "Mr. Sean A. Power CPA", "age": 42, "title": "CFO, Corporate Secretary & Treasurer", "yearBorn": 1982, "fiscalYear": 2024, "totalPay": 780600, "exercisedValue": 0, "unexercisedValue": 8840500}, {"maxAge": 1, "name": "Ms. Jenna  Bosco", "title": "Senior Vice President of Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Waldman", "title": "Chief Commercialization Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 3, "overallRisk": 10, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 30.96, "open": 30.98, "dayLow": 30.65, "dayHigh": 31.5, "regularMarketPreviousClose": 30.96, "regularMarketOpen": 30.98, "regularMarketDayLow": 30.65, "regularMarketDayHigh": 31.5, "payoutRatio": 0.0, "beta": 2.008, "trailingPE": 11.191336, "forwardPE": 31.958761, "volume": 1292357, "regularMarketVolume": 1292357, "averageVolume": 1966968, "averageVolume10days": 2449870, "averageDailyVolume10Day": 2449870, "bid": 26.4, "ask": 35.46, "bidSize": 1, "askSize": 1, "marketCap": 4921543168, "fiftyTwoWeekLow": 25.28, "fiftyTwoWeekHigh": 46.48, "allTimeHigh": 233.4375, "allTimeLow": 0.95625, "priceToSalesTrailing12Months": 9.252795, "fiftyDayAverage": 33.9048, "twoHundredDayAverage": 34.9366, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4655091200, "profitMargins": 0.84128, "floatShares": 140382097, "sharesOutstanding": 158759451, "sharesShort": 23579473, "sharesShortPriorMonth": 23608291, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.14850001, "heldPercentInsiders": 0.06784, "heldPercentInstitutions": 0.63942003, "shortRatio": 14.64, "shortPercentOfFloat": 0.1942, "impliedSharesOutstanding": 158759451, "bookValue": 4.256, "priceToBook": 7.2838345, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "earningsQuarterlyGrowth": 99.746, "netIncomeToCommon": 447472992, "trailingEps": 2.77, "forwardEps": 0.97, "lastSplitFactor": "100:5625", "lastSplitDate": 1335744000, "enterpriseToRevenue": 8.752, "enterpriseToEbitda": 45.272, "52WeekChange": 0.046943545, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 31.0, "targetHighPrice": 60.0, "targetLowPrice": 13.0, "targetMeanPrice": 44.28571, "targetMedianPrice": 49.0, "recommendationMean": 1.77778, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 131582000, "totalCashPerShare": 0.9, "ebitda": 102826000, "totalDebt": 254540000, "quickRatio": 2.532, "currentRatio": 3.825, "totalRevenue": 531897984, "debtToEquity": 41.919, "revenuePerShare": 3.643, "returnOnAssets": 0.07975, "returnOnEquity": 1.11956, "grossProfits": 453927008, "freeCashflow": -94664496, "operatingCashflow": -70073000, "earningsGrowth": 120.5, "revenueGrowth": 0.928, "grossMargins": 0.85341, "ebitdaMargins": 0.19332, "operatingMargins": 0.18159, "financialCurrency": "USD", "symbol": "TGTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "TG Therapeutics, Inc.", "longName": "TG Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1763167393, "regularMarketTime": 1763154000, "exchange": "NCM", "messageBoardId": "finmb_143627354", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.129202, "regularMarketPrice": 31.0, "firstTradeDateMilliseconds": 1272893400000, "postMarketChangePercent": 0.0061281268, "postMarketPrice": 31.0019, "postMarketChange": 0.0018997192, "regularMarketChange": 0.0400009, "regularMarketDayRange": "30.65 - 31.5", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1966968, "fiftyTwoWeekLowChange": 5.7199993, "fiftyTwoWeekLowChangePercent": 0.22626579, "fiftyTwoWeekRange": "25.28 - 46.48", "fiftyTwoWeekHighChange": -15.48, "fiftyTwoWeekHighChangePercent": -0.33304647, "fiftyTwoWeekChangePercent": 4.6943545, "earningsTimestamp": 1762176600, "earningsTimestampStart": 1762176600, "earningsTimestampEnd": 1762176600, "earningsCallTimestampStart": 1762176600, "earningsCallTimestampEnd": 1762176600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 2.77, "epsForward": 0.97, "epsCurrentYear": 2.89463, "priceEpsCurrentYear": 10.709486, "fiftyDayAverageChange": -2.9048004, "fiftyDayAverageChangePercent": -0.085675195, "twoHundredDayAverageChange": -3.9365997, "twoHundredDayAverageChangePercent": -0.112678386, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "hasPrePostMarketData": true, "displayName": "TG Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]